Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Parallel Group, Multi-center Study to Investigate Pharmacodynamic Effects After Daily Administration of Vilaprisan or Ulipristal Acetate for 8-12 Weeks in Patients With Uterine Fibroids for Whom Hysterectomy is Planned

Trial Profile

A Randomized, Open-label, Parallel Group, Multi-center Study to Investigate Pharmacodynamic Effects After Daily Administration of Vilaprisan or Ulipristal Acetate for 8-12 Weeks in Patients With Uterine Fibroids for Whom Hysterectomy is Planned

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2018

At a glance

  • Drugs Vilaprisan (Primary) ; Ulipristal
  • Indications Uterine leiomyoma
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Bayer
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 23 Aug 2018 Planned End Date changed from 6 Oct 2019 to 6 Oct 2020.
    • 23 Aug 2018 Planned primary completion date changed from 30 Aug 2019 to 30 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top